Web of Science: 24 cites, Scopus: 26 cites, Google Scholar: cites,
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders : a Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
Blauvelt, Andrew (SW Locust St., Suite G, Portland, USA)
Papp, Kim A. (Waterloo, Canada)
Griffiths, Christopher E. M. (Manchester, UK)
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Weisman, Jamie (Medical Dermatology Specialists, Inc., Atlanta, GA USA)
Dutronc, Yves (Indianapolis, IN USA)
Kerr, Lisa Farmer (Indianapolis, IN USA)
Ilo, Dapo (Indianapolis, IN USA)
Mallbris, Lotus (Indianapolis, IN USA)
Augustin, Matthias (Hamburg, Germany)
Universitat Autònoma de Barcelona

Data: 2017
Resum: Patients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A. Our aim was to assess the response to ixekizumab in patients with moderate-to-severe plaque psoriasis who did not respond adequately to etanercept using a post-hoc analysis in two phase III studies. For the subanalyses in two phase III trials (UNCOVER-2 and -3), non-response was defined by either failure to have a static physician global assessment (sPGA) of 0/1 in UNCOVER-2 or failure to have at least 75% improvement in psoriasis area and severity index (PASI 75) in UNCOVER-3 at Week 12 of each study. Non-responders treated with twice-weekly etanercept 50 mg in the first 12 weeks received two injections of placebo at Week 12 (4-week wash-out period), followed by ixekizumab every 4 weeks (Q4W) for Weeks 16-60. Non-responders to placebo in the first 12 weeks were administered ixekizumab 160 mg at Week 12, followed by ixekizumab Q4W for Weeks 16-60. After switching to ixekizumab Q4W, a substantial proportion of patients with moderate-to-severe psoriasis who did not respond to etanercept experienced rapid and durable improvement in all efficacy evaluations. Among sPGA 0/1 (UNCOVER-2) and PASI 75 (UNCOVER-3) non-responders to etanercept, 73. 0% achieved sPGA 0/1 and 78. 2% achieved PASI 75, respectively, after 12 weeks of ixekizumab treatment. Safety profiles in patients switched from etanercept to ixekizumab were similar to those in patients switched from placebo to ixekizumab. Patients who were non-responders to etanercept after 12 weeks, as defined by failure to meet sPGA 0/1 (UNCOVER-2) or PASI 75 (UNCOVER-3), achieved high levels of response 12 weeks after switching to ixekizumab. Studies are registered with ClinicalTrials. gov (NCT01597245 and NCT01646177).
Nota: Altres ajuts: NCT01597245 and NCT01646177 and the post hoc analyses of these studies presented in this manuscript were funded by Eli Lilly and Company.
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès
Document: Article ; recerca ; Versió publicada
Publicat a: American Journal of Clinical Dermatology, Vol. 18 (january 2017) , p. 273-280, ISSN 1179-1888

DOI: 10.1007/s40257-016-0246-9
PMID: 28074446


8 p, 420.3 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació Biomèdica Sant Pau
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2018-04-16, darrera modificació el 2023-01-03



   Favorit i Compartir